- This narrative review synthesizes fourteen original studies covering nearly 220,000 patients from over 1,000 centres worldwide.
- It focuses on platelet concentrate and fresh frozen plasma use in adult cardiac surgery and how hemostatic therapy varies between centres.
- Platelet and plasma transfusion rates differed significantly across centres, and patient and procedural characteristics do not fully explain these differences.
- Viscoelastic tests have improved assessment in some settings but have not eliminated variation, which the authors attribute partly to hospital culture, organization, thresholds and human factors.
Latest papers
Results for “transfusion cardiac restrictive OR transfusion cardiac liberal”.
Sorted by publication date, not import date. Recent filters exclude papers with only a publication year; find those under All years.
AI-generated abstract summaries can contain errors. Verify findings against the original paper before applying them to patient care.
Last successful paper check: 16 Nov 2026 17:18 UTC.
0 newly discovered papers saved; these are not necessarily published today.
2 papers awaiting AI summaries. Summary processing had an error; paper-fetch status is separate.
Background checks run while the server is active. This does not guarantee a daily run if hosting sleeps.
2 papers awaiting AI summaries. Summary processing had an error; paper-fetch status is separate.
Background checks run while the server is active. This does not guarantee a daily run if hosting sleeps.
- This narrative review of red blood cell transfusion thresholds draws on 2021–2026 trials, meta-analyses, and guidelines identified through PubMed and Google Scholar searches.
- It compares restrictive (Hb 7–8 g/dL) and liberal (Hb above 10 g/dL) strategies, then considers population-specific exceptions and ultra-restrictive thresholds (Hb <6–7 g/dL).
- The 2025 Cochrane update (48 trials, >20,000 participants) reported that restrictive strategies reduced the proportion receiving at least one transfusion by 41%, without increasing 30-day mortality or major morbidity.
- Restrictive thresholds appear safe in stable critically ill patients, non-cardiac surgery, and acute GI bleeding, while acute MI, neurocritical care, thalassemia, and hematologic malignancies need individualized approaches.
- This scoping review (PRISMA-ScR) mapped 57 primary studies and 15 reviews on 4-factor PCC in adults undergoing on-pump cardiac surgery.
- The comparator was FFP, and reported PCC dosing ranged from fixed 500-4000 IU to weight-based 15-30 IU/kg.
- Evidence consistently suggests PCC reduces chest tube output and transfusion versus FFP, though effect sizes vary; no pooled estimates are reported.
- The authors conclude that gaps remain on optimal dose, timing, viscoelastic targets, and fibrinogen sequencing, with limited cost-effectiveness data and rare serious adverse events.